ASO/siRNA Target Design Service

ASO/siRNA Target Design Service

1. Background

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) represent the next generation of precision nucleic acid therapeutics. By recognizing target RNAs through sequence-specific base pairing, these modalities achieve precise regulation of gene expression and have become important therapeutic strategies for rare diseases, genetic disorders, neurodegenerative diseases, and metabolic conditions. ASOs exert their effects primarily through RNase H-mediated mRNA degradation or steric-blocking mechanisms, while siRNAs leverage the RNA-induced silencing complex (RISC) to cleave target mRNA with even greater target specificity. Compared to conventional small molecules and antibody-based drugs, nucleic acid therapeutics offer distinct advantages—including a broad target landscape, shortened design cycles, and sequence programmability—enabling therapeutic intervention against targets that have traditionally been considered undruggable. These modalities have secured an increasingly important strategic position in global biopharmaceutical pipelines.

With multiple ASO and siRNA drugs now approved worldwide across a range of indications—including spinal muscular atrophy, hereditary transthyretin amyloidosis, acute hepatic porphyria, and hypercholesterolemia—the clinical value and commercial viability of nucleic acid therapeutics have been firmly established. At the same time, the global nucleic acid drug pipeline continues to expand rapidly, with a growing number of candidate molecules advancing into preclinical and clinical development stages, reflecting a market outlook that positions this field as one of the most high-growth sectors in biopharmaceuticals today.

Nevertheless, the success of nucleic acid drug development remains critically dependent on precise target identification and rational sequence design. A high-quality ASO or siRNA sequence must simultaneously satisfy: high target specificity, strong binding affinity, favorable pharmacokinetic properties, low off-target risk, and manageable immunogenicity. Poorly designed sequences may result in insufficient on-target activity, non-specific binding, or safety liabilities—factors that have historically been key drivers of drug development failures.

In recent years, international regulatory bodies including ICH, FDA, EMA, PMDA, CDE, and the Oligonucleotide Safety Working Group (OSWG) have successively issued dedicated technical guidance documents, establishing clear and systematic safety requirements for ASO/siRNA therapeutics. ZhuHai GeneRulor maintains a deep understanding of these regulatory requirements and industry consensus. Drawing upon years of safety assessment expertise, we have integrated state-of-the-art bioinformatics algorithms with curated professional databases to establish a comprehensive ASO/siRNA Target Design Platform, offering clients an end-to-end solution from target identification to sequence optimization.

Figure 1. Overview of Key Regulatory Guidance Documents from ICH, FDA, EMA, PMDA, and CDE

2. Design Principles

ASO/siRNA target design is grounded in Watson-Crick base-pairing principles, employing a multi-dimensional sequence feature analysis framework to systematically identify optimal target sites across the entire genome. The design workflow encompasses three core phases:

（1）Phase 1: Primary Candidate Screening

Based on target gene transcript information, candidate sequences are generated across functional regions of the mRNA and pre-mRNA, including exons, introns, and untranslated regions (UTRs). Fundamental filtering criteria—such as sequence length, GC content, and thermodynamic parameters—are applied to rapidly exclude sequences that fail to meet design specifications, thereby building a refined preliminary candidate library.

（2）Sequence Quality Optimization

Shortlisted sequences undergo multi-dimensional evaluation:

①Off-target Risk Assessment: Sequence homology alignment is performed to identify and eliminate high-risk sequences that may interact with unintended genomic targets.

②SNP Compatibility Screening: Sequences overlapping high-frequency variant sites are excluded to ensure cross-population applicability.

③RNA Secondary Structure Analysis: The structural accessibility of the target region is assessed, with preference given to single-stranded, open-conformation regions.

④RNase H Cleavage Efficiency Prediction (ASO) / RISC Loading Efficiency Assessment (siRNA): The target degradation potential of each sequence is quantitatively evaluated.

（3）Phase 3: Chemical Modification Strategy Recommendation

Based on sequence characteristics (e.g., CpG motif liability) and mechanism of action (RNase H-dependent vs. steric-blocking), targeted chemical modification strategies are recommended for the selected high-quality sequences. These include backbone modifications (e.g., phosphorothioate linkages), sugar modifications (e.g., 2'-MOE, LNA), and base modifications (e.g., 5-methylcytosine), aimed at enhancing nuclease resistance and binding affinity while reducing immunogenicity.

Figure 2. Three-Phase Target Design and Sequence Optimization Workflow

3. Technical Features and Advantages

（1）Regulatory-Compliant Design Standards

The design workflow strictly adheres to the FDA Guidance for Industry on Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics and relevant ICH technical principles. It encompasses sequence conservation analysis, off-target risk evaluation, and SNP variant screening—dimensions specifically highlighted by regulatory authorities—ensuring that design outputs meet IND application data requirements.

（2）Multi-dimensional Sequence Quality Scoring System

A comprehensive scoring model has been built, integrating thermodynamic stability, RNA secondary structure accessibility, enzymatic cleavage efficiency, off-target risk, and SNP compatibility. By quantitatively assessing the overall performance of each candidate sequence, the system precisely identifies high-activity, low-risk optimal targets.

（3）Dual-Platform Support for ASO and siRNA

Differentiated design strategies are applied based on the distinct mechanisms of ASOs and siRNAs: ASO design emphasizes RNase H cleavage site preference analysis and gap-region optimization, while siRNA design focuses on strand thermodynamic asymmetry, RISC loading preference, and seed-region sequence optimization—ensuring that each design strategy is precisely tailored to the drug modality.

（4）End-to-End Custom Modification Solutions

Intelligent chemical modification combinations are recommended based on sequence characteristics, including: Gapmer structural optimization for ASOs, full-strand high-stability modifications for splice-modulating ASOs, and asymmetric double-strand modification for siRNAs. Dedicated immunogenicity mitigation strategies are provided for sequences containing CpG motifs, enabling clients to rapidly advance to chemical synthesis and in vitro validation.

（5）Rapid Turnaround and Reduced R&D Costs

The design cycle requires only 10 business days, significantly shortening early-phase R&D timelines. Deliverables are seamlessly compatible with downstream chemical synthesis, in vitro activity validation, and off-target effect assessment, forming a complete candidate sequence screening–validation closed loop.

4. Application Scenarios

Early-Stage Candidate Sequence Screening: In the early stages of drug development, rapidly generate and screen multiple ASO/siRNA candidate sequences for a defined target gene. Combining activity prediction with risk assessment allows prioritization of high-potential sequences for chemical synthesis and in vitro validation, thereby reducing downstream development risk.

IND Application Data Support: Deliver a regulatory-compliant target design report encompassing sequence selection rationale, multi-dimensional quality assessment data, and modification strategy descriptions. This report serves as a critical component of nonclinical safety evaluation and supports IND submission documentation.

Sequence Optimization and Secondary Development: Redesign and optimize candidate sequences with insufficient activity or identified safety concerns by adjusting the target region, refining sequence parameters, or improving the modification strategy to enhance overall sequence performance.

New Indication Exploration: Design isoform-specific sequences targeting distinct transcript variants or alternatively spliced isoforms of the same gene, supporting exploratory research into new therapeutic indications.

5. Sample Report Overview

The ASO/siRNA Target Design Report provided by ZhuHai GeneRulor is comprehensive in content and logically structured, covering a complete analytical chain from sequence screening to modification recommendations. The following illustrates the core content using an ASO design as an example (the siRNA design report follows a similar structure, with emphasis adjusted to reflect siRNA-specific mechanisms).

（1）Comprehensive Scoring and Ranking of Candidate Targets：All shortlisted candidate sequences are scored and ranked using the multi-dimensional quality assessment framework. The report presents detailed information for the Top 30 candidate sequences in tabular format, including chromosomal coordinates, sequence composition, target functional region, RNA secondary structure score, RNase H cleavage efficiency score, SNP variant frequency, and overall ranking—enabling clients to quickly identify the optimal sequences.

Figure 3. Comprehensive Scoring and Ranking of Candidate ASO Sequences

（2）RNA Secondary Structure and Target Accessibility Analysis：For the target regions of Top candidate sequences, RNA secondary structure prediction algorithms are applied to evaluate spatial accessibility. The report provides structural scores and visual analysis, annotating the distribution of single-stranded open regions and double-stranded stem regions, and clearly delineating ASO binding difficulty and potential steric-hindrance risks.

（3）SNP Variant Site Screening：Using publicly available variant databases, all known SNP sites within the regions covered by candidate sequences are systematically screened and annotated with minor allele frequency. Sequences overlapping high-frequency variant sites are excluded to ensure binding stability and therapeutic consistency of the designed sequences across the target population.

（4）CpG Motif Risk Assessment：The Top 5 candidate sequences are evaluated for CpG motif content. If a sequence harbors unmodified CpG dinucleotides, the report clearly flags the associated immunogenicity risk and provides targeted base modification recommendations in the modification section (e.g., substitution of cytosine at CpG sites with 5-methylcytosine).

Figure 4. CpG Motif Risk Assessment for Top 5 Candidate Sequences

（5）Chemical Modification Strategy Recommendations：Tiered modification strategies are provided for the Top 5 candidate sequences based on their respective sequence features and mechanisms of action:

① For RNase H-dependent ASOs: the classic Gapmer architecture is recommended (2'-MOE/LNA wing regions + central DNA gap + full-strand phosphorothioate backbone).

② For steric-blocking ASOs or splice modulation applications: full-strand high-stability modifications are recommended (e.g., fully modified morpholino oligonucleotides [PMO] or full 2'-OMe modification).

③For high-risk sequences containing CpG motifs: additional 5-methylcytosine modification is recommended to eliminate immunostimulatory activity.

The report presents the recommended modification strategy for each candidate sequence in a clear tabular format, enabling clients to directly interface with the chemical synthesis stage.

Figure 5. Chemical Modification Strategy Recommendations for Top 5 Candidate Sequences

6. Service Content and Deliverables

6.1 Service Workflow

6.2 Deliverables

Complete target design analysis report (PDF format), including design rationale, evaluation results, and modification recommendations for the Top 5 candidate sequences.

Detailed candidate sequence information file (Excel format), containing sequence coordinates, scoring details, and ranking results.

Target gene functional annotation and literature references (where applicable).

7. Submission Requirements and Project Timeline

*Note: If additional services are required—such as off-target prediction, RNA-seq validation, or chemical synthesis—these can be flexibly combined according to project needs to form a comprehensive candidate sequence screening–validation–optimization service chain.

8. References

[1] U.S. Food and Drug Administration. Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics Guidance for Industry. Draft Guidance. November (2024).

[2] Integrated DNA Technologies (IDT). Designing RNase H1 'Gapmer' Antisense Oligonucleotides. Coralville: Integrated DNA Technologies, 2024.

[3] Aartsma-Rus A, Garanto A, van Roon-Mom W, et al. Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic Acid Ther. 2023;33(1):17-25.